Suven Life Sciences reveals breakthrough with Ropanicant in depression treatment

Suven Life Sciences reveals breakthrough with Ropanicant in depression treatment

Suven Life Sciences Limited has made a significant advancement in the fight against depression, announcing positive results from a Phase-2a proof-of-concept study involving Ropanicant (SUVN-911). The drug, tested for its efficacy in treating moderate to severe Major Depressive Disorder (MDD), showed rapid improvement in depressive symptoms within the first week of treatment. This development marks […]

Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression

Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression

Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as a standalone treatment for adults with treatment-resistant depression (TRD). This application marks a significant milestone in the treatment of major depressive disorder (MDD). The American pharma major has submitted a supplemental New Drug Application (sNDA) to the […]

Sage Therapeutics, Biogen get ZURZUVAE FDA approval for postpartum depression treatment

Sage Therapeutics, Biogen get ZURZUVAE FDA approval for postpartum depression treatment

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression (PPD). The treatment is the first of its kind, offering an oral, once-daily, 14-day course that can provide rapid improvements in depressive symptoms for women with postpartum […]

Granules India gets Venlafaxine ER Capsules FDA approval

Granules India gets Venlafaxine ER Capsules FDA approval

Granules India has secured approval for its abbreviated new drug application (ANDA) for Venlafaxine Hydrochloride Extended-Release (ER) Capsules USP, 37.5 mg, 75 mg, and 150 mg from the US Food and Drug Administration (FDA). Venlafaxine ER Capsules is bioequivalent to Upjohn US 2’s Effexor XR Extended-Release Capsules, said the Indian pharma company. Venlafaxine HCl extended-release […]

Digital medicine firm Akili Interactive to merge with Social Capital Suvretta

Digital medicine firm Akili Interactive to merge with Social Capital Suvretta

Akili Interactive, a US-based digital medicine company, has agreed to merge with Social Capital Suvretta Holdings Corp. I (SCS), a special purpose acquisition company (SPAC), in a deal that values the combined entity at around $1 billion. Through the deal, Akili Interactive will become a publicly-listed company with a listing on Nasdaq under the “AKLI” […]

Sage Therapeutics secures $3.1bn worth licensing deal for zuranolone and SAGE-217 with Biogen

Sage Therapeutics secures $3.1bn worth licensing deal for zuranolone and SAGE-217 with Biogen

Sage Therapeutics has secured a global collaboration and licensing deal worth up to $3.1 billion with Biogen for two of its drug candidates intended for the treatment of depression and movement disorders. Under the terms of the deal, the two US pharma companies will jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), […]

Tenzing to acquire clinical-stage pharma company Reviva Pharmaceuticals

Tenzing to acquire clinical-stage pharma company Reviva Pharmaceuticals

Tenzing Acquisition has agreed to acquire Reviva Pharmaceuticals, a California-based clinical-stage pharma company, focused on developing therapies for addressing unmet medical needs in the areas of central nervous system, metabolic, cardiovascular, and inflammatory diseases. According to the British Virgin Islands-incorporated special purpose acquisition company, the equity value of the combined company post its merger with […]

Usona Institute gets FDA breakthrough status for psilocybin in MDD

Usona Institute gets FDA breakthrough status for psilocybin in MDD

Wisconsin-based Usona Institute has been granted breakthrough therapy designation for psilocybin from the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD). According to Usona Institute, the designation secured by psilocybin for major depressive disorder acknowledges the unmet medical need in the broad population and also the potential for significant […]